| Name | Title | Contact Details |
|---|---|---|
Dennis Hom |
Chief Financial Officer and Head Corporate Development | Profile |
Anthony Rimac |
Chief Financial Officer | Profile |
George Kemble |
Chief Executive Officer | Profile |
We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today`s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people`s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people`s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.
Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.
Aurobindo USA is committed to delivering a broad portfolio of quality, affordable generic pharmaceuticals to pharmacists and patients. Since its first US ANDA approval in 2004, Aurobindo has expanded its portfolio to include more than 125 product families and 450 individual product packages, representing a wide range of therapeutic categories. Aurobindo has been recognized as the fastest growing pharmaceutical company in 2012,* and in early 2013, thanks to the ongoing support of our customers, became one of the top 10 pharmaceutical companies, brand or generic, in terms of total prescriptions dispensed.**
Shionogi Pharma is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.